Figure 2From: Efficacy, safety and tolerability of ongoing statin plus ezetimibe versus doubling the ongoing statin dose in hypercholesterolemic Taiwanese patients: an open-label, randomized clinical trial Percent change from baseline in lipid levels after 8 weeks of treatment (ITT population). Back to article page